Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04158479
Recruiting Observational

China Extracorporeal Life Support Registry

NCT04158479 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Anzhen Hospital
Phase
Observational
Started
2017-01-01
Last updated
2024-04-09

Condition(s) studied

Cardiogenic ShockCardiac ArrestHeart FailureAcute Respiratory Distress SyndromeAcute Respiratory Failure

Investigational drug(s) / intervention(s)

ECMO

ECMO: ECMO for circulatory and/or respiratory support

Study summary

Extracorporeal life support (ECLS), also known as extracorporeal membrane oxygenation (ECMO), is an extracorporeal technique of providing effective cardiac and respiratory support to patients with lungs and/or heart failure. There was a growth in ECLS cases, centers, and center scale in China during the past decade.

This multi-center registry was conducted by Chinese Society of Extracorporeal Life Support. The objectives were to investigate China statistics of ECLS and to evaluate the short-term and long-term outcomes of patients with ECLS.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients receiving ECMO for circulatory and/or respiratory support Exclusion Criteria: * Refusal of consent

Primary outcome measure(s)

  • All-cause mortality — 30 days

Trial sites (1)

FacilityCityRegionStatus
Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University Beijing Beijing Municipality Recruiting

More Beijing Anzhen Hospital trials in China

Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome Starting soon
Helium-free Magnetocardiography Guided Therapy for Stable Coronary Artery Disease - A Randomized Controlled Trial Recruiting
CLEAR Trial: CA330 Cytokine Adsorption Column for Anticoagulant/Antiplatelet Patients in Non-Elective CPB Surgery. Starting soon
Acute Myocardial Infarction Clinical Intelligent Decision Support System Active, not recruiting
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis Recruiting

Other trials for the same condition

Mobile Applet for Weight Management in Obese Heart Failure Patients Recruiting
The Effect of Physical Activity Level Evaluated by Wrist-wearable Devices on Cardiovascular Disease Risk and Other Outcomes in Peritoneal Dialysis Patients Enrolling by invitation
Bolt CSP-M Holter Study Active, not recruiting
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial Starting soon
The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04158479 on ClinicalTrials.gov ↗ ← All trials in China